arrow
N

Nicholas F. Grigoropoulos

Singapore General Hospital
H指数:15
被引数:730

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of C-MYC/BCL2 Double Expression on Survival Outcomes After Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma-A Nationwide Retrospective Analysis in Singapore
2024-12-270
PRE
The Endothelial Activation and Stress Index (EASIX) Score Improves Risk Stratification for Double Expressor Diffuse Large B-Cell Lymphoma (DEL)

内皮活化与应激指数(EASIX)评分可改善双表达型弥漫大B细胞淋巴瘤(DEL)的风险分层

BLOOD
IF23.1
2024-11-050
PRE
Machine Learning Classification of Spatial Patterns of Malignant Cells Reveals Implications in Prognosis and Tumor Microenvironment Composition in Lymphoma

机器学习对恶性细胞空间模式的分类揭示了其在淋巴瘤预后和肿瘤微环境组成方面的意义

BLOOD
IF23.1
2024-11-050
PRE
Single Cell Resolution Spatial Modeling Uncovers Survival-associated Phenotypes in Diffuse Large B Cell Lymphoma
2024-04-150
PRE
Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma
2023-04-182
OAAI
Patterns of oncogene co-expression at single cell resolution influence survival in diffuse large B-cell lymphoma
2023-04-040
PRE
Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide
2023-02-0610
OAAI
A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort
2022-07-056
OAAI
CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma
2021-11-0113
OAAI
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes
2021-10-169
OAAI
Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis
2021-10-0149
OA
Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma (vol 34, 3413, 2020)
LEUKEMIA
IF13.4
2021-03-080
OAAI
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial
2021-02-2715
OAAI
No association between ECSIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma
2020-10-131
OAAI
Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma
LEUKEMIA
IF13.4
2020-08-0560
OAAI